Targeting CLEC9A delivers antigen to human CD141⁺ DC for CD4⁺ and CD8⁺T cell recognition.

ABSTRACT: DC-based vaccines that initiate T cell responses are well tolerated and have demonstrated efficacy for tumor immunotherapy, with the potential to be combined with other therapies. Targeting vaccine antigens (Ag) directly to the DCs in vivo is more effective than cell-based therapies in mouse models and is therefore a promising strategy to translate to humans. The human CD141⁺ DCs are considered the most clinically relevant for initiating CD8⁺ T cell responses critical for killing tumors or infected cells, and they specifically express the C-type lectin-like receptor CLEC9A that facilitates presentation of Ag by these DCs. We have therefore developed a human chimeric Ab that specifically targets CLEC9A on CD141⁺ DCs in vitro and in vivo. These human chimeric

SUBMITTER: Tullett KM 

PROVIDER: S-EPMC5033826 | biostudies-literature | 2016 May

REPOSITORIES: biostudies-literature